EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors

Ping Zhang, Jiaxing Pan, Shutong Lin, Bo Peng, Caiyan An, Junjing Zhang, Leiming Xu, Yi Lai, Haijun Yu, Zhiai Xu

Advanced Drug Delivery Reviews · 2025-09 · 224 · 115620

DOI: 10.1016/j.addr.2025.115620 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025-09. Verfasst von Ping Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China; State Key Laboratory of Chemical Biology & Cente…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Drug Delivery Systems, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 229 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has emerged as a promising strategy for pancreatic ductal adenocarcinoma (PDAC) therapy, yet its clinical efficacy suffers from the immunosuppressive tumor microenvironment (ITM). This ITM contributes to immune resistance by impeding the cancer immune (CI) cycle at multiple stages, including impaired antigen release and presentation, inadequate T cell priming and activation, restricted T cell infiltration, and compromised T cell cytotoxicity within the tumor. To address these challenges, smart drug delivery systems have emerged as a transformative strategy to precisely modulate the CI cycle, thereby reversing the ITM and restoring the anti-tumor immunity. In this review, we systematically dissect the clinical landscape of PDAC immunotherapy, outline key mechanisms of impaired CI cycle to drive immunotherapy resistance, and explore smart drug delivery platforms for reinitiating CI cycle. We further discuss the latest preclinical advances of precisely engineered drug delivery systems, and provide a perspective on their potential to harness the CI cycle and overcome immunotherapy resistance in PDAC. This review not only summarizes current progress but also provides a forward-looking perspective on next-generation immunotherapies, emphasizing the role of neuro-immune interactions and the rational design of spatiotemporally tunable, circadian rhythm-adaptable drug delivery systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDrug Delivery SystemsCarcinoma, Pancreatic DuctalHumansTumor MicroenvironmentImmunotherapyAnimalsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Cancer immune cycleDrug delivery systemsImmune resistancePancreatic cancerStimuli-responsive

Autor:innen und Institutionen

  • School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China; State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Acad…
  • State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China; Department of Gastroenterology, Xinhua Hospital Shanghai Jiao…
  • State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China.
  • Information Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Inner Mongolia Key Laboratory of Allergic Diseases, Foundational and Translational Medical Research Center, Hohhot First Hospital, Hohhot 010030, China.
  • Department of Hepato-Biliary Surgery, Department of Surgery, Hohhot First Hospital, Hohhot 010030, China. Electronic address: zhang.jj@vip.163.com.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Zhang, P., Pan, J., Lin, S., Peng, B., An, C., Zhang, J., Xu, L., Lai, Y., Yu, H., & Xu, Z. (2025). Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors. Advanced Drug Delivery Reviews, 224, 115620. https://doi.org/10.1016/j.addr.2025.115620

Vancouver

Zhang P, Pan J, Lin S, Peng B, An C, Zhang J, et al. Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors. Advanced Drug Delivery Reviews. 2025;224:115620. doi:10.1016/j.addr.2025.115620

BibTeX
@article{Zhang2025,
  author = {Zhang, Ping and Pan, Jiaxing and Lin, Shutong and Peng, Bo and An, Caiyan and Zhang, Junjing and Xu, Leiming and Lai, Yi and Yu, Haijun and Xu, Zhiai},
  title = {Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors},
  journal = {Advanced Drug Delivery Reviews},
  year = {2025},
  volume = {224},
  pages = {115620},
  doi = {10.1016/j.addr.2025.115620}
}
Kostenlos starten →